Daniel T Starczynowski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5158429/publications.pdf

Version: 2024-02-01

62	7,316	218677	189892
papers	citations	26 h-index	50 g-index

66	66	66	16557
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia, 2022, 36, 438-451.	7.2	13
2	Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes. Cancer Discovery, 2022, 12, 250-269.	9.4	14
3	IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Current Opinion in Hematology, 2022, 29, 8-19.	2.5	42
4	Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood Advances, 2022, 6, 1186-1192.	5.2	10
5	TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell, 2022, 29, 298-314.e9.	11.1	23
6	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine, 2022, 14, eabb7695.	12.4	13
7	Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. Journal of Hematology and Oncology, 2022, 15, .	17.0	6
8	IKAROS and MENIN in synergy in AML. Nature Cancer, 2022, 3, 528-529.	13.2	0
9	Inflammation rapidly recruits mammalian GMP and MDP from bone marrow into regional lymphatics. ELife, 2021, 10, .	6.0	5
10	Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. Journal of Experimental Medicine, 2021, 218, .	8.5	88
11	Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell, 2021, 28, 1074-1089.e7.	11.1	37
12	TNF-Î±-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling. Cell Reports, 2021, 36, 109386.	6.4	15
13	Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell, 2021, 28, 1966-1981.e6.	11.1	49
14	Preclinical Activity of the Clinical Stage Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Splicing Mutant Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2021, 138, 2597-2597.	1.4	1
15	Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML. Blood, 2021, 138, 206-206.	1.4	0
16	Heterozygous Mutations in DDX41 Cause Erythroid Progenitor Cell Defects. Blood, 2021, 138, 148-148.	1.4	0
17	FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Blood Cancer Journal, 2020, 10, 98.	6.2	13
18	TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease. Experimental Hematology, 2020, 90, 18-29.	0.4	20

#	Article	IF	Citations
19	TNFAIP3 Plays a Role in Aging of the Hematopoietic System. Frontiers in Immunology, 2020, 11, 536442.	4.8	13
20	TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis. Cell Reports, 2020, 30, 2776-2790.e6.	6.4	27
21	Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology, 2020, 21, 535-545.	14.5	92
22	Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. Journal of Clinical Investigation, 2020, 130, 2017-2023.	8.2	23
23	Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS. Blood, 2020, 136, 32-33.	1.4	2
24	The Inherited MDS Gene DDX41 Is Essential for Ribosomal RNA Processing through Regulation of Snorna Biogenesis. Blood, 2020, 136, 40-40.	1.4	0
25	HHEX expression drives AML development. Blood, 2020, 136, 1575-1576.	1.4	0
26	Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine, 2019, 11, .	12.4	54
27	The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3161-3171.	1.3	12
28	U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology, 2019, 21, 640-650.	10.3	165
29	Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease. Current Opinion in Cell Biology, 2019, 58, 85-94.	5.4	34
30	SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML. Blood, 2019, 134, 4224-4224.	1.4	12
31	Cell-Intrinsic Inflammation Drives Progression from Myelodysplastic Syndromes to Leukemia. Blood, 2019, 134, 2983-2983.	1.4	0
32	The Inherited MDS Gene DDX41 Is Required for Ribosome Biogenesis and Cell Viability. Blood, 2019, 134, 773-773.	1.4	0
33	Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity. Blood, 2019, 134, 727-727.	1.4	18
34	Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study. Blood, 2019, 134, 4271-4271.	1.4	0
35	TRAF6 Mediates Basal Activation of NF-Î¹B Necessary for Hematopoietic Stem Cell Homeostasis. Cell Reports, 2018, 22, 1250-1262.	6.4	62
36	Chronic innate immune signaling results in ubiquitination of splicing machinery. Cell Cycle, 2018, 17, 407-409.	2.6	3

#	Article	IF	Citations
37	KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Advances, 2018, 2, 2491-2504.	5.2	29
38	Chronic immune response dysregulation in MDS pathogenesis. Blood, 2018, 132, 1553-1560.	1.4	159
39	Genomic Landscape of Multiple Myeloma with Elevated Lactate Dehydrogenase. Blood, 2018, 132, 470-470.	1.4	0
40	GMP-ing to Spatial Conclusions about Emergency and Leukemic Myelopoiesis. Cell Stem Cell, 2017, 20, 579-581.	11.1	4
41	Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nature Immunology, 2017, 18, 236-245.	14.5	85
42	Inhibition of IRAK1 Ubiquitination Determines Glucocorticoid Sensitivity for TLR9-Induced Inflammation in Macrophages. Journal of Immunology, 2017, 199, 3654-3667.	0.8	21
43	Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leukemia Research, 2016, 50, 85-94.	0.8	15
44	A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nature Medicine, 2016, 22, 727-734.	30.7	68
45	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
46	Genomic instability establishes dependencies on acquired gene regulatory networks: A novel role of p62 in myeloid malignancies with del(5q). Molecular and Cellular Oncology, 2015, 2, e1014219.	0.7	2
47	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Experimental Hematology, 2015, 43, 858-868.e7.	0.4	28
48	Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptorâ€“TRAF6 signaling. Journal of Experimental Medicine, 2015, 212, 1967-1985.	8.5	93
49	Deconstructing innate immune signaling in myelodysplastic syndromes. Experimental Hematology, 2015, 43, 587-598.	0.4	29
50	IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival. Oncotarget, 2015, 6, 43395-43407.	1.8	34
51	Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML. Blood, 2015, 126, 3690-3690.	1.4	0
52	Role of microRNA-146a in normal and malignant hematopoietic stem cell function. Frontiers in Genetics, 2014, 5, 219.	2.3	41
53	Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-ÎºB Gene Network. Cell Reports, 2014, 8, 1328-1338.	6.4	64
54	p62 Is Required for Stem Cell/Progenitor Retention through Inhibition of IKK/NF-ÎºB/Ccl4 Signaling at the Bone Marrow Macrophage-Osteoblast Niche. Cell Reports, 2014, 9, 2084-2097.	6.4	56

#	Article	IF	Citations
55	Errant innate immune signaling in del(5q) MDS. Blood, 2014, 124, 669-671.	1.4	4
56	IRAK1: oncotarget in MDS and AML. Oncotarget, 2014, 5, 1699-1700.	1.8	18
57	Sqstm1 Is Required to Retain Hematopoietic Stem Cell/ Progenitors As a Negative Regulator of Macrophage-Dependent Inflammatory Signaling in the Bone Marrow Osteoblastic Niche. Blood, 2014, 124, 350-350.	1.4	0
58	Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. Cancer Cell, 2013, 24, 90-104.	16.8	168
59	Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood, 2012, 120, 858-867.	1.4	94
60	Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood, 2011, 117, 595-607.	1.4	105
61	Identification of miR-145 and miR-146a as mediators of the 5qâ€“ syndrome phenotype. Nature Medicine, 2010, 16, 49-58.	30.7	588
62	Innate Immune Signaling in the Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2010, 24, 343-359.	2.2	43